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Strengths and limitations of this study
 ► This study will be the first to evaluate the mecha-
nism of the impact of a financial incentive initiative 
involving Clinical Commissioning Groups (CCGs) to 
improve antibiotic prescribing in primary care prac-
tices in England.
 ► The investigation of multiple mediators in this 
study will help to identify the contributions of mul-
tiple strategies in translating the effects of Quality 
Premium (QP) while unpacking the extent of the ef-
fect of specific mediators.
 ► Due to the limited data on practice-level interven-
tions or strategies that might potentially mediate the 
effect of the QP on antibiotic prescribing, we will not 
be able to extensively investigate the mechanism of 
QP impact at the practice level.
 ► Nevertheless, extensive investigations will be con-
ducted at CCG level where the QP initiative is imple-
mented and rewards paid out.
AbStrACt
Introduction The persistent development and spread of 
resistance to antibiotics remain an important public health 
concern in the UK and globally. About 74% of antibiotics 
prescribed in England in 2016 was in primary care. The 
Quality Premium (QP) initiative that rewards Clinical 
Commissioning Groups (CCGs) financially based on the 
quality of specific health services commissioned is one of 
the National Health Service (NHS) England interventions 
to reduce antimicrobial resistance through reduced 
prescribing. Emerging evidence suggests a reduction in 
antibiotic prescribing in primary care practices in the UK 
following QP initiative. This study aims to investigate the 
mechanism of impact of this high-cost health-system 
level intervention on antibiotic prescribing in primary care 
practices in England.
Methods and analysis The study will constitute 
secondary analyses of antibiotic prescribing data for 
almost all primary care practices in England from the NHS 
England Antibiotic Quality Premium Monitoring Dashboard 
and OpenPrescribing covering the period 2013 to 2018. 
The primary outcome is the number of antibiotic items per 
Specific Therapeutic group Age-sex Related Prescribing 
Unit (STAR-PU) prescribed monthly in each practice or 
CCG. We will first conduct an interrupted time series using 
ordinary least square regression method to examine 
whether antibiotic prescribing rate in England has changed 
over time, and how such changes, if any, are associated 
with QP implementation. Single and sequential multiple-
mediator models using a unified approach for the natural 
direct and indirect effects will be conducted to investigate 
the relationship between QP initiative, the potential 
mediators and antibiotic prescribing rate with adjustment 
for practice and CCG characteristics.
Ethics and dissemination This study will use secondary 
data that are anonymised and obtained from studies that 
have either undergone ethical review or generated data 
from routine collection systems. Multiple channels will 
be used in disseminating the findings from this study to 
academic and non-academic audiences.
IntroduCtIon
The persistent development and spread of 
resistance to antimicrobials, especially anti-
biotics, remain an important public health 
concern in the UK1 and globally.2 3 Antimi-
crobial resistance (AMR) is a major threat 
to the treatment and control of infectious 
diseases as drug-resistant infections are char-
acterised by prolonged morbidity, increased 
risk of disabilities, death and cost of health-
care.4 A 2014 review estimated that consis-
tent increases in AMR would lead to about 
10 million deaths per year by 2050.5 Inappro-
priate prescribing and use of antibiotics in 
healthcare practices, especially primary care, 
are integral to the development and spread 
of resistance.6 7
About 74% of the antibiotics prescribed in 
England in 2016 was in primary care.8 The 
high rate of antibiotic prescribing in primary 
care has been associated with increased AMR.9 
While some of the antibiotics prescribed 
in primary care settings are appropriate, a 
substantial proportion are cases where anti-
biotics are not clinically indicated, such as 
suspected respiratory tract conditions, which 
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Figure 1 Conceptual model. The direct effect is represented by the path between the QP initiative (predictor) and 
antibiotic prescribing rate (outcome). *Not directly observed within our data. AMS, antimicrobial stewardship; CCG, Clinical 
Commissioning Group; CMO, Chief Medical Officer; QP, Quality Premium; TARGET, Treat Antibiotics Responsibly, Guidance, 
Education, Tools.
can be self-limiting.9 10 Uncertainties about diagnosis, 
(perceived) patient expectations for antibiotics, occu-
pational pressure (eg, consultation rate) and previous 
experiences are some of the identified drivers of overpre-
scribing in primary care practices.11–16
Interventions such as antibiotic stewardship 
programmes, education and training initiatives targeted 
at prescribers and patients, financial incentives, among 
others have been implemented in England to reduce 
AMR through reduced prescribing. In particular, the 
Quality Premium (QP) is a National Health Service 
(NHS) England initiative established in 2013 to reward 
Clinical Commissioning Groups (CCGs) financially based 
on the quality of specific health services considered to 
be of national or local priority and commissioned over a 
specific period.17 Improvement of antibiotic prescribing 
in primary care was one of the national priorities in the 
2015/2016 guidance,18 constituting 10% of the premium 
awarded from 2016/2017 to date.19 20 Key aspects of the 
‘improved antibiotic prescribing’ priority are reduc-
tions in the number of antibiotics prescribed in primary 
care facilities across England and in the proportion of 
broad-spectrum antibiotics prescribed in primary care 
(2015–2017).19 Part of the requirements in the 2015/2016 
QP guidance for demonstrating improved antibiotic 
prescribing by CCGs was a reduction in the number 
of antibiotics prescribed in primary care by 1% of the 
mean value in England in 2013/2014 (ie, 1.61 items per 
Specific Therapeutic group Age-sex Related Prescribing 
Unit (STAR-PU)). This was further increased to 4% in the 
2016/2017 guidance.
Emerging evidence suggests a reduction in antibiotic 
prescribing in primary care practices in the UK following 
the QP initiative.21 22 Prescribing data from England show 
a reduction of about 2.7 million antibiotic items between 
2014/2015 and 2016/2017 financial year.23 Eighty-eight 
per cent of the CCGs in England achieved the target 
of reducing antibiotic prescribing in the first 2 years of 
QP.21 Also, there has been a significant reduction in the 
proportion of broad-spectrum antibiotics prescription 
with 83% of the CCGs meeting their target in the first 
2 years.21 Such reductions in antibiotic prescribing would 
be expected to contribute to reductions in the develop-
ment of resistance.24 However, little is known about the 
mechanisms by which the QP initiative impacted on anti-
biotic prescribing in primary care practices.
The impact of interventions on specific outcomes 
is sometimes explained by a series of events. Potential 
mediators are important in assessing causal relation-
ships like that between QP and antibiotic prescribing 
in primary care practices in England, where a poten-
tial mediator is a variable that hypothetically medi-
ates the effect of QP on the outcome. The conceptual 
model shown in figure 1 demonstrates the hypothesised 
pathways for the impact of the QP initiative on antibi-
otic prescribing and subsequently AMR. The model is copyright.
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developed based on conceptual and empirical evidence 
from existing literature and the results of qualitative and 
survey studies conducted as initial stages of the broader 
STEP-UP (Improving the uptake and SusTainability of 
Effective interventions to promote Prudent antibiotic 
Use in Primary care)25 project that includes the current 
study. The conceptual model will be further validated 
through a stakeholder workshop with key antibiotic stew-
ardship personnel, primary care prescribers and CCG 
representatives.
Our conceptual model suggests that in addition to its 
direct impact, the QP initiative acts by stimulating and 
enhancing the adoption of existing strategies to reduce 
and optimise antibiotic prescribing. In investigating the 
potential pathways connecting QP to reductions in anti-
biotic prescribing, we will be examining the hypothesis 
that factors like the Chief Medical Officer’s (CMO) letter, 
Treat Antibiotics Responsibly, Guidance, Education, Tools 
(TARGET) toolkit, antibiotic auditing, benchmarking, 
local incentives at CCG level, prescribers and patients’ 
antimicrobial stewardship (AMS) education/training can 
transmit part of the influence of the QP initiative to anti-
biotic prescribing.
First implemented in September 2014, the CMO letter, 
which provided social norm feedback to primary care 
practitioners in England whose antibiotic prescribing 
rate was in the top 20%, reduced antibiotic prescribing by 
3.3% in 6 months in a randomised trial.26 The criteria for 
selecting practices that received the letters in the subse-
quent years changed with the addition of measures like 
a change in antibiotic prescribing over time and whether 
practices have previously been sent CMO letter.
Another important mediator hypothesised in our 
conceptual model is AMS education/training of 
prescribers and patients. Educating and training 
prescribers on the importance of antibiotic stewardship 
and ways to promote prudence can help prescribers 
make better decisions on when an antibiotic is indicated 
and can also improve patients’ knowledge on the appro-
priate use of antibiotics. AMS interventions targeted at 
patients can improve their knowledge of when antibiotics 
are not needed and increase confidence and skills on 
how to self-care, which can result in reduced consulta-
tions for self-limiting illness and thus reduced antibiotic 
prescriptions.
TARGET is a toolkit developed by the Public Health 
England (PHE), the Royal College of General Prac-
titioners and other professional societies to promote 
prudent antibiotic use among prescribers and patients in 
primary care.27 The intervention comprises of multiple 
resources (patient information leaflets on infection 
management and antibiotic use, self-assessment check-
list for prescribers, antibiotic audit toolkits, interactive 
workshop presentations, national antibiotic management 
guidance, training resources and resources for clinical 
and waiting areas) to provide clinicians and patients with 
the motivation and skills to use antibiotics prudently.27 
A qualitative study evaluating prescribers’ attitude and 
perception about the TARGET toolkit reported that 
general practitioners described it as useful and important 
in improving their prescribing behaviours and the expec-
tations of their patients.28 The use of resources like the 
TARGET antibiotics workshop has been shown to reduce 
antibiotic prescribing rate in a randomised controlled 
trial.29
We hypothesise that the implementation of the QP 
initiative informed the initiation or wider use of these 
strategies indicated in the conceptual model as mediators, 
which will subsequently influence antibiotic prescribing 
at primary care practices.
The implementation of the QP initiative in NHS England 
constitutes a natural experiment and offers an opportu-
nity to investigate the preintervention and postinterven-
tion periods to understand the mechanism of impact of 
the QP intervention in reducing antibiotic prescribing 
rates in primary care practices.30 Given the ethical and 
practical constraints in manipulating exposure in such 
an intervention, a natural experimental design offers a 
practical approach to understand the overall effect and 
mechanism of interventions like QP that offers financial 
incentives for clinical compliance. The publication of the 
2015/2016 QP Guidance18 constitutes the ‘intervention’, 
with periods before this as the ‘control’.
Study aim and objectives
Using routinely collected population-level data on anti-
biotic prescribing in England, this study aims to address 
the research question: What are the mechanisms and 
mediators of the impact of a high-cost health-system 
level intervention, the ‘antibiotic prescribing quality 
premium’? We will investigate the difference in antibiotic 
prescribing rate pre-QP and post-QP initiative to establish 
its direct, indirect (through mediators) and total effects 
in reducing antibiotic prescribing in primary care prac-
tices in England.
MEthodS And AnAlySIS
Study design
Contemporary evaluations of the effectiveness of 
health policies go beyond estimating their total effect 
on outcomes. Mediation analysis decomposes the total 
effect of an intervention into separate causal pathways,31 
enabling an understanding of why and how policies work 
by estimating the direct and indirect effects of the expo-
sure.32 We will conduct mediation analyses investigating 
the potential mediators of the impact of QP on antibiotic 
prescribing in primary care in England, establishing the 
direct and indirect effects of the QP initiative.
data sources
The study will constitute secondary analyses of antibiotic 
prescribing data from NHS England covering the period 
2013 to 2018. CCGs were established in England in April 
2013 following the Health and Social Care Act 2012.33 
Data on antibiotic prescribing in primary care at CCG level 
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will be sourced from the NHS England Antibiotic Quality 
Premium Monitoring Dashboard, which is produced by 
the NHS Business Services Authority (BSA).34 Primary 
Care prescribing data are publicly available from the 
NHS BSA website. The dataset contains the number of 
antibiotic items (STAR-PU) prescribed in each CCG from 
the financial year 2015/2016 to 2018/2019, with data for 
October 2018 the latest at the time of this protocol. Data 
for the period 2013 to 2015 will be mapped to CCG level 
from the practice-level data.
Practice-level antibiotic prescribing data will be sourced 
from OpenPrescribing, an Evidence-Based Medicine 
DataLab project by the University of Oxford. OpenPre-
scribing publishes monthly antibiotics prescribing data 
from August 2013, with data for October 2018 the latest 
at the time of this protocol. Practice-level antibiotic 
prescribing data from OpenPrescribing is not STAR-PU 
weighted, so the extracted data will be STAR-PU weighted 
using figures from the 2013 Item-based age–sex weighting 
for oral antibacterials14 and the number of registered 
patients in each age–gender category in a practice for 
each specific month.
Overall, the dataset offers coverage of at least 3 years 
postintervention given that antibiotic prescribing became 
a QP priority in March 2015. This will be important in 
investigating the immediate direct and indirect effects of 
the QP initiative while giving an insight into the sustain-
ability of the identified effects (if any) in the long-term.
Variables
The predictor will be a binary variable indicating the 
implementation of the QP intervention. The interven-
tion will include all periods after March 2015 when the 
2015/2016 QP guidance in England was published, while 
the control will be periods prior to this. The primary 
outcome of interest is the rates of antibiotic prescribing 
at CCG level in England, which will be a continuous 
variable indicating the number of items (per STAR-PU) 
prescribed per month.
To account for differences in practice and CCG char-
acteristics that can contribute to variance in antibiotic 
prescribing, we will be adjusting for the number of general 
practitioners in each practice (from the NHS Workforce 
data),35 the index of multiple deprivation (from the 
Department for Communities and Local Government),36 
prevalence of comorbidities (asthma, chronic obstruc-
tive pulmonary disease, diabetes, cancer, chronic kidney 
disease (from the NHS Quality and Outcomes Framework 
database)),37 the prescribing rate of other non-antibiotic 
drugs (opioids and benzodiazepines) and seasonal influ-
enza vaccination rate (from PHE).38
Mediator variables will be derived from the question-
naire data from a PHE survey,39 with 187 of the 209 AMS 
leads representing CCGs in England and data from 
other organisations that have evaluated the interventions 
treated as potential mediators in this study. In the PHE 
survey, participants were required to complete question-
naire items, which included their adoption of national 
and local strategies in their respective CCG to enable them 
to meet QP targets on antibiotic prescribing in primary 
care. The mediator variables will be binary or continuous 
variables, indicating the adoption of key interventions 
and intermediaries that are hypothesised to reflect in the 
integration of the QP guidance in improving antibiotic 
prescribing in primary care practices.
handling missing data
Over the period covered by this study (2013–2018), there 
have been changes in the number of practices and CCGs 
in England. Some practices have closed, new practices 
opened and some CCGs merged over the period; as such, 
we will have missing values for some observations. To 
maximise the use of existing observations, we will retain 
all observed values in the main analysis and impute the 
missing values using multiple approaches.40 Missing 
values for the period before a new CCG was formed 
through merger of pre-existing CCGs will be imputed 
using the mean value of the CCGs that constitutes the 
merger; subsequently, these closed CCGs will be dropped 
from the dataset. Other missing values in this study will 
be handled using multiple imputation method on Mplus 
V.8.2. We will run a separate imputation model for the 
practice and CCG level datasets, the results will be aver-
aged across 20 imputed datasets. Complete case analysis 
will be conducted as part of the sensitivity analyses for this 
study to examine the consistency of the results from the 
imputed set.
Statistical analysis
Our first analysis will be an interrupted time series to 
investigate whether antibiotic prescribing rate in England 
has changed over time, and how such changes, if any, are 
associated with the QP implementation in March 2015. 
This will be conducted using the ordinary least square 
regression method41 to assess whether the 2015/2016 QP 
establishment resulted in a shift in the level and trend 
in antibiotic prescribing in primary care in England 
compared with the period before the intervention. Using 
the practice-level dataset, a univariate time series with the 
mean antibiotic items (STAR-PU weighted) prescribed in 
all primary care practices in England for each month will 
be conducted using the ITSA function on Stata, with post-
trend specification to show a postintervention trend. The 
Cumby-Huizinga general test for autocorrelation will be 
used for general specification test of serial correlation in 
the time series data.42
A new QP guideline was implemented each financial 
year with changes in the prescribing rate target and the 
proportion that improved prescribing constituted in 
the QP award for each year. Our mediation analyses will 
investigate the effects of the QP by comparing antibiotic 
prescribing rate in the financial year before its imple-
mentation to each subsequent year postimplementation; 
as such, our dataset for the mediation analyses will have 
the control group as the financial year before QP and the 
intervention group as a specific post-QP implementation 
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year. Three analyses will be conducted for each of the 
three financial years since QP establishment. This will 
enable us to compare the effects of the different target 
levels that have been set over the years and the propor-
tions of the QP award attributed to improvement in anti-
biotic prescribing.
Using a unified model for the natural direct and indi-
rect effects,31 we will investigate the relationship between 
the QP initiative, the potential mediators and antibiotic 
prescribing rate with adjustment for the practice and 
CCG characteristics. This approach addresses the issues 
associated with the traditional approach to mediation 
analysis that obtains natural direct and indirect effect 
estimates through a non-trivial combination of parameter 
estimates from multiple models for the regression of the 
mediator and that of the outcome.32 43 Also, the unified 
model is applicable to nonlinear regressions, different 
measurement types for outcome and mediator variables, 
and allows for interaction between the exposure and the 
mediator.31
We will first fit single-mediator models with each medi-
ator separately modelled using the medeff function in 
Stata.44 With the single-mediator models, we will be able 
to establish the individual influence of each potential-me-
diator variable. Variables that showed a mediating effect 
in the single-mediator models will be added to build a 
multiple-mediator model using a sequential mediation 
analysis method.45
A sequential multiple-mediator analysis is preferred 
to merely summing the effects of the single mediators 
because the sum may differ from the joint mediated 
effect, particularly as our potential mediators may influ-
ence one another.45 Modelling all the significant medi-
ators together provides a more accurate assessment of 
the mediation effects and causal relationship,46 47 while 
assessing the indirect effect of a group of mediators in 
explaining how and why the intervention impacts on the 
outcome. The ordering of the mediators in the sequen-
tial mediation analysis will be based on evidence from the 
literature and the outcome of our stakeholders’ work-
shop designed to identify possible pathways between the 
predictor, mediators and outcome. The workshop that 
will validate our conceptual model will also enable us to 
identify what mediators affect one another and inform 
interactions to include in our model. All analysis will be 
conducted in the Stata statistical package V.15.1.
Sensitivity analyses
Sensitivity analyses using dummy implementation dates 
of 1 to 3 months before and after the actual month each 
of the QP guidance were published will be conducted 
to assess the difference between the time the guidance 
is published and the dissemination of information and 
development of local arrangements by the CCGs. These 
analyses will further help to investigate the anticipatory 
effect of the policy and whether lag in implementation 
attenuates the effect of the intervention.
Also, we will conduct separate analysis with the outcome 
variable (antibiotic prescribing rate) as a binary variable 
(indicating whether each CCG achieved the required rate 
of reduction in antibiotic prescribing as stated in the QP 
guidance for each year) to examine whether the classifi-
cation of the outcome variable based on achievement of 
QP target influences the results.
Subgroup analyses will be conducted on clusters 
of primary care practices based on their antibiotic 
prescribing behaviour (high and low prescribers) and 
indices of deprivation to examine whether any effect 
of the QP initiative seen in the overall population is 
different in subgroups of practices. The top and bottom 
20% antibiotic prescribers as of March 2015 will be cate-
gorised as high and low prescribers. To address the issue 
of regression to mean in subgroup analyses, we will build 
a separate model with categorisation into high and low 
prescribers based on the mean of the prescribing rate of 
practices in the last 3 months to March 2015. The use of 
mean of multiple measures will offer a better estimate 
of each practice’s true mean before the 2015/2016 QP 
initiative.48 The subgroup analysis based on the indices 
of deprivation data36 49 at primary-care practice level will 
be important in establishing the equity impact of the QP 
initiative.
lIMItAtIonS
This study has some limitations. The survey that provided 
data on mediator variables included 187 of the 209 CCGs 
existing at the time of the study. However, this sample size 
is large enough for strong statistical power, and multiple 
imputation will be used to address issues on missingness. 
Furthermore, due to the limited data on practice-level 
interventions or strategies that might potentially mediate 
the effect of the QP on antibiotic prescribing, we will not 
be able to extensively investigate the mechanism of QP 
impact at the practice level. Nevertheless, extensive inves-
tigations will be conducted at CCG level where we have 
more data on potential mediators.
In 2013, the Primary Care Trusts in England, which 
were responsible for planning and commissioning health-
care services at the primary care level, were transformed 
to CCGs.50 As such, our investigations are restricted to the 
CCG era. This is important as the QP initiative is imple-
mented and rewards paid out at CCG level.
We recognise that the causal interpretation of any effect 
from our mediation analysis rests on assumptions such as 
sequential ignorability and exchangeability. Causal infer-
ence from this analysis will be limited given that our data 
are observational with the absence of random assign-
ment of cases to treatment and mediator levels, as well 
as the likelihood of unmeasured confounders. The rate 
of consultation for conditions where antibiotics might be 
prescribed is one of the unmeasured confounders in our 
study. This has not been accounted for in our analyses 
as these data are not available nationally at the practice 
level.
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dISCuSSIon
Although the QP intervention has been reported to have 
been effective in reducing antibiotic prescribing,22 there 
remain important gaps in the evidence base for this inter-
vention, especially in relation to its mechanism of impact. 
This study will be the first to evaluate the mechanism of 
the impact of a financial incentive initiative involving 
CCGs to improve antibiotic prescribing in primary 
care practices in England. If our study identifies some 
key mediators, like other interventions implemented 
in similar time or in response to the QP initiative, that 
explain the indirect effect of the QP intervention on anti-
biotic prescribing, this will provide important evidence 
on the effectiveness of the implementation of a package 
of interventions on antibiotic prescribing. The investiga-
tion of multiple mediators in this study will also help to 
highlight the contributions of multiple factors in trans-
lating the effects of QP while unpacking the extent of the 
effect of specific mediators.
Evidence on the mechanism of impact of strategies like 
QP will be important in improving its uptake and sustain-
ability while maximising its potential in reducing antibi-
otic prescribing in primary care settings.
Finally, financially incentivised strategies for clinical 
compliance have been criticised for their ability to result 
in unintended consequences.51 In the case of the QP 
initiative, unintended consequences like not prescribing 
antibiotics in cases where they are indicated are possible. 
However, some of the QP response strategies that we 
hypothesised as potential mediators (such as prescribers’ 
AMS education/training) have the ability to mitigate this 
unintended consequence. By comparing the prescribing 
rate before and after the QP initiative and identifying the 
strategies that explain its effect, we will generate evidence 
that will be important in considerations of the future 
of this intervention and revisions that may help reduce 
potential unintended consequences.
Patient and public involvement
This study will use secondary data mostly from routine 
collection system and will not directly involve patients or 
the public. The dissemination of the results will include 
communication channels and public engagement events 
that will involve primary care practitioners and CCG 
representatives.
Ethics and dissemination
Prescribing data from NHS BSA and NHS Digital are 
generated from routinely collected prescribing data on 
items that have been dispensed in primary care prac-
tices in England. The survey that produced the data on 
mediator variables was registered with the PHE Research 
Support and Governance Office (RSGO) and approved 
by PHE Research Ethics and Governance Group (REGG) 
and Health Research Association (HRA).
Multiple channels will be used in disseminating the 
findings from this study to academic and non-academic 
audiences, which will include an engagement workshop 
with our stakeholder network, presentations in scientific 
conferences, publication in peer-reviewed journals and 
press conference coinciding with paper publications.
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